前不久,香港特区政府推出了《医疗创新2030计划》,宣布投入1200亿港元设立生物医药专项基金,并配套税收优惠政策(企业所得税降至15%、研发费用200%加计扣除),直接推动港股医疗板块大幅上涨。药明生物(02269)、信达生物(01801)等龙头企业股价创历史新高。 受此影响,华夏—WindESG蒲公英30指数近期表现一直较为亮眼。年初至今,该指数上涨22.24%,近一月日均成交额为39.51...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.